🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the infection, according to health experts.

An International Public Health Issue

The sexually transmitted infection are increasing around the world, with data suggesting over 82 million new cases each year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are increasingly worried about the surge in drug-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Results and Global Access

According to findings detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The research involved hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the ability to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have voiced positive views. Access to a single-dose, oral treatment such as this is described as a "revolutionary step" for managing the epidemic. This is considered vital to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.